Funding confirms Viz.ai as healthcare AI market leader
SAN FRANCISCO & TEL AVIV, Israel–(BUSINESS WIRE)–#AI–Viz.ai, the developer of the first synchronized healthcare software (Viz) using artificial intelligence (AI), today announced a $50 million Series B funding. The funding round was led by Greenoaks with participation from Threshold Ventures, CRV along with existing investors GV and Kleiner Perkins.
Viz.ai has emerged as one of the most exciting and fastest growing healthcare companies in the artificial intelligence (AI) space. It was recently named by Forbes as one of “America’s Most Promising Artificial Intelligence Companies.” Through the De Novo FDA pathway, Viz.ai introduced the concept of computer-aided triage software; Viz uses deep learning algorithms to identify a suspected large vessel occlusion, a particularly disabling type of stroke, in a CT scan and alerts the stroke team specialist. This happens in minutes. By alerting the right doctor at the right time and synchronizing care, Viz has the potential to significantly reduce the time to treatment and greatly increase a patient’s chances of a good outcome.
“Viz.ai’s mission is to improve access to lifesaving treatments. In stroke, by saving time for the hospital system, we can achieve significant cost savings for the payer and most importantly, improved outcomes for the patient. This round of funding will enable us to expand the benefits of Synchronized Care to more disease states and geographies, democratizing the quality of health care globally,” said Chris Mansi, CEO of Viz.ai.
Viz.ai’s acute ischemic stroke software is now available in over 300 hospitals across the U.S. “Viz.ai shortens time to treatment, increases the number of patients able to receive lifesaving therapy, and allows us to provide the best care for our patients. With stroke being the number one cause of long-term disability, every minute counts! Viz.ai is reducing the impact of this devastating disease and saving lives,” said J Mocco1, MD, Professor and Vice Chair of the Department of Neurosurgery, Mount Sinai Health System.
Viz.ai is positioned to make a big impact on healthcare as a whole by curating the exponentially expanding healthcare data and making it immediately actionable for medical providers. “We see Viz.ai as the future of how healthcare is delivered. With rising costs and more focus on value-based care, there needs to be an emphasis on delivering the highest quality care in the shortest amount of time while reducing costs,” said Neil Shah of Greenoaks.
Viz.ai is the leader in applied artificial intelligence in healthcare. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.
Viz.ai is located in San Francisco and Tel Aviv.
Greenoaks is a private investment firm that makes concentrated, long-term investments in internet-enabled businesses globally. Greenoaks was founded in 2012 and is based in San Francisco.
1 Dr. J. Mocco is an investor in Viz.ai.
Maginn Consulting LLC for Viz.ai